A bill to provide for the establishment, within the Food and Drug Administration, of an Abraham Accords Office to promote and facilitate cooperation between the Food and Drug Administration and entities in Abraham Accords countries wishing to work with the agency in order to develop and sell products in the United States, and for other purposes.
About This Bill
Committee
Latest Action · December 12, 2024
Read twice and referred to the Committee on Foreign Relations.
This bill establishes a new Abraham Accords Office within the Food and Drug Administration to help companies and manufacturers from countries that have signed the Abraham Accords navigate U.S. regulatory processes for drugs and medical devices. The office would be headed by a director and physically located in one of the Abraham Accords countries within two years of enactment, staffed with FDA personnel assigned by the Secretary of Health and Human Services. The office would provide technical assistance on manufacturing standards, share information about FDA approval pathways, and help companies prepare applications for drug and device approvals in the United States. The Secretary of State and Secretary of Health and Human Services can temporarily suspend these activities for up to six months if necessary for national security or other specified reasons, with the ability to renew such suspensions. The program would automatically end twelve years after the office is established, and the FDA must report to Congress within three years on the office's progress and the manufacturers it has assisted.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.